10 research outputs found
High level resistance to gentamicin and vancomycin in enterococci isolated from poultry in Argentina
In chicken husbandry, antimicrobial resistance among enterococci has been observed. Glycopeptides and gentamicin MinimumInhibitory Concentrations in fecal poultry enterococci were determined. Glycopeptide and high-level gentamicin resistance(HLGR) genes were investigated. E. faecalis (n = 105) and E. faecium (n = 70) were the predominant species. In E. faecalis, HLGR(19%) was observed. In high-level gentamicin resistant E. faecalis, presence of aac (6´) -Ie-aph (2´´)-Ia gene was confirmed. VanA E.faecium (7.1%) were found, with HLGR (20%) and high-level streptomycin resistance (40%). vanA genotype was detected inglycopeptide resistant E. faecium (100%). These results highlight the presence of horizontally transferable antimicrobialresistance determinants in E. faecalis and E. faecium recovered from poultry. Existence of enterococcal reservoirs in poultry shouldbe taken into account as a potential source of antimicrobial resistance genes, strengthening their potential spread to humansthrough the food chain of horizontal transferable resistance determinants.Fil: Delpech, Gastón. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Sparo, Mónica Delfina. Universidad Nacional del Centro de la Provincia de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Ceci, Monica. Centro de Estudios Bioquímicos, Tandil, Prov. Bs.as.; ArgentinaFil: Baldaccini, Maria Beatriz. Universidad Nacional del Centro de la Provincia de Buenos Aires; ArgentinaFil: Garcia Allende Leonardo. Centro de Estudios Bioquímicos, Tandil, Prov. Bs.as.; Argentin
Bacteremic Pneumococcal Pneumonia: a Longitudinal Study in 279 Adult Patients from a Single Center
Background: Bacteremic pneumococcal pneumonia (BPP) is the most common clinical presentation of invasive pneumococcal disease (IPD). Although it has been extensively studied, there is little knowledge in our region in relation to burden of disease, demographic and outcome features.
Methods: We conducted a prospective, longitudinal, observational study from 1989 to 2015 in adult patients with BPP, in order to deepen our knowledge of the characteristics of this disease in our community hospital in Tandil, Argentina.
Results: 279 patients were included. The mean incidence was 2.8/1000 admissions with a sharp decrease in the last two years, reaching 0.8/1000 admissions. Mean patient age was 60 years. Comorbidities were found in 65% of the cases. Non-respiratory symptoms occurred in 50% of cases. Infiltrates on chest x ray were predominantly unilateral (75%) and lobar (57%). Regarding severity, a low PSI score I-II-II was found in 178 patients (64%), 60 (22%) were admitted to ICU, 40 (14%) required mechanical ventilation, and 21 (8%) developed empyema. Penicillin resistance was not found. Mortality was 18% (49/279), and by a multivariate analysis it was associated with confusion (OR= 5.44), age\u3e80 years (OR =5.72), leukopenia (OR =5.73) and dyspnea (OR=7.87).
Conclusions: In this study of 279 bacteremic pneumococcal pneumonia we reinforce previous knowledge on this disease regarding incidence and clinical features and confirm a considerable an early mortality associated to age and severity of disease at onset. Recent changes in incidence of BPP in adults could be secondary to herd effect of PVC 13 a vaccine that is mandatory in children in our community since 2012
Enterocin AP-7121: combination with colistin against human multi-drug resistant Gram-negative pathogens
The significant prevalence of Gram-negative bacteria as health-care associated pathogens and their increased antimicrobial multi-drug resistance highlight the need for new therapeutic options. Colistin is a conventional antimicrobial currently employed for the treatment of nosocomial infections caused by multi-drug resistant Gram negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii complex with a main drawback, its toxicity. Doses of this drug, and its toxic effects, can be potentially reduced by using it combined with bacteriocins. AP-7121 is an enterocin produced by the probiotic strain Enterococcus faecalis CECT7121. The aim of this study was to investigate the synergistic activity of AP-7121 combined with colistin against multi-drug resistant Gram-negative pathogens. P. aeruginosa (n: 3) only susceptible to colistin and A. baumannii complex (n: 3) only susceptible to colistin and tigecycline were included. These human isolates were recovered from blood cultures (hemoculture) of patients with catheter-related bloodstream infections at the Intensive Care Unit (Hospital Ramon Santamarina de Tandil Argentina). Minimum Inhibitory Concentration (MIC) for AP, colistin, and colistin/AP-7121 combination against Gram-negative bacteria was assayed (micro-dilution method, CLSI 2018). In vitro bactericidal activity of AP alone or combined with colistin (MIC/4), for assessing a synergistic effect, was studied carrying out time-kill curves. Samples were obtained for viable cell counts (0, 4, 8 and 24 h). MIC and time-kill curves were carried out three times, in duplicate. Results were expressed as their average values. All isolates were resistant to AP (MICAP-7121 > 128 mg/L). Colistin showed anti-P. aeruginosa (MICcolistin 0.5 mg/L) and anti-A. baumannii complex (MICcolistin 0.5-1.0 mg/L) activity in each isolate. Colistin/AP-7121 Combination showed bactericidal activity against P. aeruginosa (MICcolistin/AP-7121 ≤ 0.06/11-0.12/16 mg/L) and A. baumannii (MICcolistin/AP-7121 ≤ 0.12-0.20/16 mg/L). A synergistic effect (colistin/AP-7121) was observed at 4-8 and 24 h for P. aeruginosa (-1.8 to -3.8 Δlog10 CFU/mL) and for A. baumannii complex isolates (-2.0 to -3.8 Δlog10 CFU/mL). AP-7121 is a candidate as an alternative option for the combination with colistin, against human P. aeruginosa and A. baumannii complex isolates producers of bloodstream infections. Their synergistic activity against these bacteria, leads to a bactericidal activity of AP, with lower MIC values and a potential reduction of colistin toxicity, to be thoroughly investigated
New bacteriocin of E. Faecalis CECT7121: synergy studies against multidrug-resistant enterococci isolated from bovine mastitis
Bovine mastitis impacts negatively on animal production and on the quality of milk. AP-CECT7121, a new bacteriocin produced by Enterococcus faecalis CECT7121, shows a variety of interesting biological properties with potential use in clinical Veterinary practice, without undesirable side effects. It is a peptide with a wide spectrum of bactericidal activity against Gram positive bacteria and bacteriostatic activity against some Gram negative bacteria. The aim of this study was to evaluate the synergism of AP-CECT7121 associated with gentamicin against multidrug-resistant enterococci isolated from bovine mastitis. N: 4 multidrug-resistant E. faecium strains isolated from different mastitic dairy cows were tested. Animals from dairy farms, located in the Province of Buenos Aires-Argentina, during the period 2014-2015 were included. AP-CECT7121 potency was assessed by time-kill curves alone or with sub-inhibitory concentrations of gentamicin. High level gentamicin resistance was not observed in any enterococcal isolate. Viable counts, after 0, 2, 4, 8 and 24 h of incubation, were carried out. The AP-CECT7121exhibited bactericidal activity alone against all tested enterococci. The association with gentamicin slightly enhanced bactericidal activity against all isolates of E .faecium. Bactericidal activity of AP-CECT7121 alone and associated with subinhibitory concentrations of gentamicin against enterococci proved that this peptide constitute an attractive candidate for its use as a natural therapeutic tool for control and prevention of bovine mastitis produced by multi-resistant bacteria such as vancomycin-resistant E. faecium.Fil: Delpech, Gastón. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Ceci, Monica Andrea. No especifíca;Fil: Bistoletti, Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Sanchez Bruni, Sergio Fabian. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Sparo, Mónica Delfina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaLXI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIV Reunión Anual de la Sociedad Argentina de Inmunología; XLVIII Sociedad Argentina de Farmacología Experimental, VII Reunión Anual de la Sociedad Argentina de Nanomedicina y V Congreso Nacional de la Asociación Argentina de Ciencia y Tecnología de Animales de LaboratorioMar del PlataArgentinaSociedad Argentina de Investigación ClínicaSociedad Argentina de InmunologíaSociedad Argentina de Farmacología ExperimentalSociedad Argentina de NanomedicinaAsociación Argentina de Ciencia y Tecnología de Animales de Laboratori
Infecciones severas por Acinetobacter baumannii en un hospital general
Acinetobacter baumannii es un patógeno emergente hospitalario. En las últimas décadas, se ha comprobado su rol como agente etiológico de infecciones severas y brotes en los hospitales, con altas tasas de morbi-mortalidad, particularmente en pacientes inmunocomprometidos internados en Unidades de Terapia Intensiva. Asimismo, se ha observado que las cepas intra-hospitalarias de A. baumannii expresan resistencia múltiple a los antimicrobianos. El objetivo del presente estudio fue investigar las infecciones severas por A. baumannii en un hospital general de la Provincia de Buenos Aires. Se trató de un estudio observacional, prospectivo, transversal. Período: enero-julio 2015. Se obtuvieron muestras de líquidos de punción, para cultivo microbiológico, solicitadas por orden médica. La caracterización fenotípica a nivel de género y especie se realizó mediante pruebas convencionales. El perfil de resistencia antimicrobiana in vitro se investigó cuantitativamente mediante la determinación de la Concentración Inhibitoria Mínima (CIM), según las recomendaciones del Clinical and Laboratory Standards Institute (2015). Antimicrobianos ensayados: cefotaxima, ceftazidima, ceftriaxona, cefepime, aztreonam, imipenem, meropenem, ciprofloxacina, amikacina, gentamicina, trimetoprima/sulfometoxazol y colistin. Se incluyeron N = 11 pacientes, admitidos en: Unidad de Terapia Intensiva (n: 6), Servicio de Cirugía (n: 2), Servicio de Clínica Médica (n: 2) y Unidad de Diálisis (n: 1). Se registró una mortalidad del 81,8% y factores de co-morbilidad: disfunción respiratoria (45,4%), inmunosupresión (36,4%), cirugía previa (9,1%) y alcoholismo (9,1%). Se recuperaron n: 11 cepas de A. baumannii, una por cada paciente. Los aislamientos fueron realizados a partir de muestras de sangre (54,5%), líquido pleural (36,4%) y líquido abdominal (9,1%). La totalidad de las cepas de A. baumannii expresó resistencia antimicrobiana múltiple. Se detectó resistencia a cefotaxima (100%), ceftazidima (100%), ceftriazona (100%), cefepime (100%), amikacina (81,8%), gentamicina (81,8%), aztreonam (72,7%), trimetoprima/sulfametoxazol (72,7%), ciprofloxacina (54,5%), imipenem (45,5%) y meropenem (45,5%). No se observó resistencia a colistin en el 100% de las cepas estudiadas. Esta investigación ha brindado evidencia sobre la necesidad de realizar una vigilancia continua de la susceptibilidad antimicrobiana en A. baumannii de origen hospitalario. Se debe recalcar la expresión de multi-resistencia observada, además de la diseminación de las cepas hacia distintos Servicios del establecimiento sanitario, sin limitarse a la Unidad de Terapia Intensiva.Fil: Delpech, Gastón. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Lisarrague, Sabina. Municipalidad de Tandil (buenos Aires). Sistema Integrado de Salud Publica.; ArgentinaFil: Ranno, Gabriela. Municipalidad de Tandil (buenos Aires). Sistema Integrado de Salud Publica.; ArgentinaFil: Ceci, Monica Andrea. Centro de Estudios Bioquímicos. Tandil; ArgentinaFil: Rivulgo, Virginia Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Sanchez Bruni, Sergio Fabian. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Sparo, Mónica Delfina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaXLVII Reunión Anual de la Sociedad Argentina de Farmacología Experimental; VI Congreso Iberoamericano de Ciencias Farmacéuticas y III Congreso Sudamericano de Biofarmacia y FarmacocinéticaCordobaArgentinaSociedad Argentina de Farmacología ExperimentalUniversidad de la República Uruguay. Facultad de Químic
Six-Month Multicenter Study on Invasive Infections Due to Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis in Argentina
During a 6-month period, 95 invasive infections due to Streptococcus pyogenes and group C or group G Streptococcus dysgalactiae subsp. equisimilis were recorded from 40 centers of 16 cities in Argentina. We describe here epidemiologic data available for 55 and 19 patients, respectively, associated with invasive infections due to S. pyogenes and S. dysgalactiae subsp. equisimilis. The associated isolates and 58 additional pharyngeal isolates were genotyped and subjected to serologic and/or antibiotic susceptibility testing. Group A streptococcal emm type distribution and strain association with toxic shock appeared to differ somewhat from results found within the United States; however, serologic characterization and sof sequence typing suggested that emm types found in both countries are reflective of shared clonal types
Protective effect of Enterococcus faecalis CECT7121 against Trichinella spiralis infection in mice
Trichinellosis is an important parasitic zoonosis produced by the ingestion of raw or undercooked meat infected by Trichinella spiralis larvae. At the present, the pharmacological treatment against Trichinellosis in human is unsuccessful. Therefore, the potential of viable Enterococcus faecalis CECT7121 culture, administered by oral route, in mice against T. spiralis infection was evaluated. Eighteen BALB/C mice were divided in two groups (n=9) as follow: A- Experimental Group: E. faecalis CECT7121 strains were administered daily in a dose of 10 9 UFC/mL in 300 µL for five consecutive days. B-Negative control Group: animals received 300 µL of sterile sodium chloride. On day 5 of treatment, whole mice were infected with 450 T. spiralis larvae. Four mice, from both experimental and control group, were sacrificed on day 6 post infection for assessing the amount of T. spiralis adults from the small intestine. At day 28 post infection the remaining mice from each group were sacrificed and the tongue processed in order to estimate the muscle larval burden in that tissue, used as surrogate marker of the number of larvae per g (LPG) of tissue. The test used for groups statistical comparison was Mann- Whitney. A difference of p0.05). However, the percentage of LPG reductions obtained in tongue tissue after 28 days post- infection increased 62% (p <0.01) in mice treated with E. faecalis CECT7121 as preventive. The quantification of T. spiralis adults in the intestinal content alone was not indicative of presence or absence of protective response when compared with samples obtained from mice tongue tissue. The protective response of E. faecalis CECT7121 against T. spiralis infection will be a contribution to improve the conventional therapeutic against Trichinellosis.Fil: Schofs, Laureano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Sparo, Mónica Delfina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Delpech, Gastón. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Dominguez, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Ceci, Monica Andrea. Universidad Nacional del Centro de la Provincia de Buenos Aires. Escuela Superior de Ciencias de la Salud; ArgentinaFil: Lissarrague, Sabina. Universidad Nacional del Centro de la Provincia de Buenos Aires. Escuela Superior de Ciencias de la Salud; ArgentinaFil: de Yaniz, María Guadalupe. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Sanchez Bruni, Sergio Fabian. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaLXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de LaboratorioMar del PlataArgentinaSociedad Argentina de Investigación ClínicaAsociación Argentina de Farmacología ExperimentalSociedad Argentina de BiologíaSociedad Argentina de ProtozoologíaAsociación Argentina de NanomedicinasAsociación Argentina de Ciencia y Tecnología de Animales de Laboratori
Systemic Exposure, Tissue Distribution, and Disease Evolution of a High Solubility Ciprofloxacin−Aluminum Complex in a Murine Model of Septicemia Induced by Salmonella enterica Serotype Enteritidis
A new pharmaceutical derivative obtained by stoichiometric complexation of ciprofloxacin (CIP) with aluminum (CIP-complex) has been investigated and reported in this study. Such product has high solubility in the gastrointestinal pH range and was successful in the development of optimized formulations while maintaining its antimicrobial potency. The systemic exposure, tissue distribution, and the disease evolution after given CIP-complex were assessed. The systemic exposure and distribution in intestines, lungs, and kidneys after a single intragastric administration of CIP-complex and CIP given alone, used as reference, were performed in Balb-C mice at a dose of 5 mg CIP/kg. For the assessment of the disease evolution assay, mice were infected with a virulent strain of Salmonella enterica serotype Enteritidis and treated intragastrically once or twice daily during 5 consecutive days with solutions of CIP-complex or the reference. Clinical follow up and survival was measured during 15 days post inoculation and health state was scored during this period from 0 to 5. CIP-complex showed a 32% increase in Cmax, an earlier Tmax, and a smaller AUC0–12 than the reference. Maximum tissue concentrations (0.5–1 h) were significantly higher in CIP-complex (447% in intestine, 93% in kidney, and 44% in lungs). In the infection model used in this study, survival in CIP-complex versus CIP groups was 40% versus 20% (twice-daily administration) and 30% versus 0% (once-daily administration). Health state of the survivors of CIP-complex group (5/5) was higher than CIP group (3/5). The greater effectiveness of CIP-complex is attributed to the higher levels of CIP in the intestine. Our results supported the fact that CIP-complex is a promising candidate to develop dose-efficient formulations of CIP for oral administration.Fil: Breda, Susana Andrea. Universidad Nacional de Cordoba. Facultad de Ciencias Quimicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Cordoba. Unidad de Investigacion y Desarrollo en Tecnologia Farmaceutica; ArgentinaFil: Guzman, Maria Laura. Universidad Nacional de Cordoba. Facultad de Ciencias Quimicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Cordoba. Unidad de Investigacion y Desarrollo en Tecnologia Farmaceutica; ArgentinaFil: Confalonieri, Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tandil. Centro de Investigacion Veterinaria de Tandil; ArgentinaFil: Gonzalez, Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tandil. Centro de Investigacion Veterinaria de Tandil; ArgentinaFil: Sparo, Monica. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tandil. Centro de Investigacion Veterinaria de Tandil; ArgentinaFil: Manzo, Ruben Hilario. Universidad Nacional de Cordoba. Facultad de Ciencias Quimicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Cordoba. Unidad de Investigacion y Desarrollo en Tecnologia Farmaceutica; ArgentinaFil: Sanchez Bruni, Sergio Fabian. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tandil. Centro de Investigacion Veterinaria de Tandil; ArgentinaFil: Olivera, Maria Eugenia. Universidad Nacional de Cordoba. Facultad de Ciencias Quimicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Cordoba. Unidad de Investigacion y Desarrollo en Tecnologia Farmaceutica; Argentin